Description
Tegafur, gimeracil and oteracil (Tegafur/gimeracil/oteracil), a fluorouracil derivative, is an oral biological anti-cancer agent made up of tegafur (FT), gimeracil (CDHP) and oteracil (Oxo). In 1999, it was approved to treat advanced gastric cancer and then such indications as head and neck neoplasm, inoperable or unresectable breast cancer, non-small cell carcinoma, colon cancer, pancreatic cancer and bile duct cancer.
View Full Report at: http://www.marketresearchreports.biz/analysis/289094
Years of clinical application prove that tegafur, gimeracil and oteracil is a safe and effective anti-cancer drug. According to statistics, over 80% of advanced gastric cancer patients use tegafur, gimeracil and oteracil in chemotherapy, CR + PR reaching 44.6%.
According to CRI’s statistics, tegafur, gimeracil and oteracil develops fast after entering China with annual sales rising from less than CNY 20 million in 2009 to CNY 707 million in 2014 and CAGR reaching up to 110% during the period of 2009-2014, which demonstrats a bright future. Tegafur, gimeracil and oteracil enjoys a vast demand in China. Currently, tegafur, gimeracil and oteracil in the Chinese market come from the following four companies: Shandong New Time Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group Corporation, Qilu Pharmaceutical Co., Ltd, Taiho Pharmaceutical Co., Ltd and Jiangsu Hengrui Medicine Co., Ltd, among which Shandong New Time Pharmaceutical Co., Ltd has the largest market share of nearly 50% with sales reaching up to CNY 348 million in 2014.
Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/289094
The market size of tegafur, gimeracil and oteracil in China is expected to keep growing.
Readers can get at least the following information through this report:
market share of manufacturers of tegafur, gimeracil and oteracil in Chinese market
price of tegafur, gimeracil and oteracil in Chinese market major manufacturers of tegafur, gimeracil and oteracil in China share of different dosage forms of tegafur, gimeracil and oteracil in Chinese market market outlook of tegafur, gimeracil and oteracil in China
The author suggests the following groups of people purchase this report:
manufacturers of antitumor drugs
investors/ research institutions interested in Chinese medicine market
any interest in Chinese medicine market, please contact CRI for customized survey service
Table of Content
1 Related Concepts of Tegafur, Gimeracil and Oteracil
1.1 Indication
1.2 Sales Status in Global Market
2 Market Profile of Tegafur, Gimeracil and Oteracil in China
2.1 Patent and Approval Status of Tegafur, Gimeracil and Oteracil in China
2.2 Major Manufacturers
2.3 Market Size
3 Survey on Sales Status of Tegafur, Gimeracil and Oteracil in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.
Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E:
[email protected]